Abstract:Background: Glucagon-like peptide 1 (GLP-1) therapies are effective for metabolic disease, but treatment cessation may lead to rapid weight and glucose rebound. We developed a novel pancreatic gene therapy (PGTx) platform enabling durable islet production of GLP-1-based peptides. Here, we assessed body composition and glycemic parameters of single-dose PGTx versus chronic semaglutide (Sema) in a murine diet-induced obesity model. Methods: Mice fed 60% high-fat diet were randomized to: single-dose intraperitoneal PGTx (1e13 vector genomes [VG], n=10), daily subcutaneous Sema (10 nmol/kg/d x 4 weeks, n=10), PGTx vehicle control (VC) (n=8), or Sema VC (n=8). Sema was withdrawn at week (wk) 4, and mice were randomized to PGTx (5e12 VG, n=5) or VC (n=5). Mean body composition and fasting glucose (FG) were assessed. A 0-5-point histopathology score was used to evaluate islet inflammation and integrity. Statistical comparisons were made to cohort baselines. Results: At wk 4, PGTx reduced fat mass by 21% and lean mass by 5% versus 16% fat mass and 5% lean mass with Sema (all, p<0.0001). Sema withdrawal led to a fat and lean mass regain to 1% and 2% below baseline, while Sema-withdrawn mice treated with PGTx maintained reductions of 17% (p<0.01) and 5% (p<0.001) at wk 8. In PGTx and Sema groups, FG reduced by 18% at wk 4 (both, p<0.0001). Sema-withdrawal resulted in FG rebound to baseline, while PGTx and PGTx-treated Sema-withdrawn mice maintained 21% (p<0.0001) and 22% (p<0.001) FG reductions at wk 8. No significant evidence of pancreas inflammation was observed with mean islet histopathology scores of <0.5 in all groups. Conclusions: Single-dose PGTx can durably improve fat mass and glycemia and maintain these metabolic parameters upon Sema withdrawal without causing pancreatic inflammation. The data indicate that PGTx has the potential to advance GLP-1 therapies by offering durable efficacy in type 2 diabetes and obesity. Disclosure A.L. Fitzpatrick: Employee; Fractyl Health, Inc. Stock/Shareholder; Fractyl Health, Inc. S. Wang: Employee; Fractyl Health, Inc. Stock/Shareholder; Fractyl Health, Inc. R. Reese: Employee; Fractyl Health, Inc. Stock/Shareholder; Fractyl Health, Inc. N. Picard: Employee; Fractyl Health, Inc. Stock/Shareholder; Fractyl Health, Inc. E. Cozzi: Employee; Fractyl Health, Inc. Stock/Shareholder; Fractyl Health, Inc. T.J. Kieffer: Employee; Fractyl Health, Inc. Stock/Shareholder; Fractyl Health, Inc. J. Caplan: Employee; Fractyl Health, Inc. Stock/Shareholder; Fractyl Health, Inc. H. Rajagopalan: Board Member; Fractyl Health, Inc. Employee; Fractyl Health, Inc. Stock/Shareholder; Fractyl Health, Inc.

GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice

Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes

Targeting GLP-1 receptor trafficking to improve agonist efficacy

Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors

PGLP-1, a Novel Long-Acting Dual-Function GLP-1 Analog, Ameliorates Streptozotocin-Induced Hyperglycemia and Inhibits Body Weight Loss.

Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls

Tesaglitazar ameliorates non-alcoholic fatty liver disease and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient mice

Design and evaluation of GLP-1 receptor G-protein biased agonist with prolonged efficacy on diabetes.

A GLP‐1/glucagon/CCK‐2 receptors tri‐agonist provides new therapy for obesity and diabetes

A Novel Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist Exhibits Weight-Lowering and Diabetes-Protective Effects.

Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity

1625-P: GS-4571, an Oral Small Molecule GLP-1R Agonist, Improves Glucose Tolerance and Suppresses Food Intake in Obese Diabetic Cynomolgus Monkeys

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1

Pharmacological Effects of EGLP-1, a Novel Analog of Glucagon-Like Peptide-1, on Carbohydrate and Lipid Metabolism

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide

Development of a C‐Terminal Site‐Specific PEGylated Analog of GLP‐1 with Improved Anti‐Diabetic Effects in Diabetic Mice

Discovery of a Novel GLP-1/GIP Dual Receptor Agonist CY-5 As Long-Acting Hypoglycemic, Anti-Obesity Agent

Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist

261-OR: ADA Presidents' Select Abstract: Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia after Semaglutide Withdrawal in a Murine Model of Obesity

Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects